Why WELL is so compelling
I think the investment case for WELL comes down to the combination of quality, growth, and valuation. Many companies have one or two of those characteristics. WELL arguably has all three.
Here are the reasons I think investors find WELL compelling:
1. It has reached significant scale
WELL is no longer a small-cap startup. It is expected to generate roughly $1.6 billion in annual revenue, making it one of the larger healthcare technology companies on the TSX.
2. Healthcare is a secular growth industry
Demand continues to rise because of:
* Aging populations
* Physician shortages
* Longer wait times
* Greater adoption of digital healthcare
These trends are likely to persist regardless of the economic cycle.
3. Recurring revenue
Much of WELL’s business comes from:
* Electronic medical records (EMRs)
* Clinics
* Digital health services
* Virtual care
* SaaS and technology offerings
Recurring revenue is generally viewed as more stable and predictable than one-time sales.
4. AI could be a major growth driver
Healthcare is one of the industries where AI has the potential to deliver meaningful productivity gains. WELL is already incorporating AI into physician workflows, documentation, and clinical operations. If AI adoption accelerates, WELL could benefit without needing to build an entirely new business.
5. Strong cash generation
Unlike many growth companies, WELL has demonstrated the ability to generate adjusted EBITDA and free cash flow, giving it flexibility to invest, reduce leverage, or make additional acquisitions.
6. Management has executed
Over the past several years, management has:
* Successfully completed numerous acquisitions.
* Expanded margins.
* Increased revenue substantially.
* Built one of Canada’s largest outpatient healthcare networks.
Execution has generally matched the strategy they laid out.
7. The valuation appears inexpensive
This is where many bullish investors focus.
Despite substantial revenue growth and improving profitability, WELL’s valuation remains modest compared with many healthcare technology peers. If the market eventually values WELL more like a healthcare technology platform than a traditional clinic operator, there could be room for multiple expansion.
8. Multiple ways to win
The company doesn’t rely on a single catalyst. Potential drivers include:
* Organic growth.
* Further acquisitions.
* Margin expansion.
* AI adoption.
* Debt reduction.
* Higher valuation multiples.
* Increased institutional ownership.
* Potential strategic interest from larger healthcare or technology companies.
Why many investors are frustrated
Perhaps the biggest surprise is that the business has improved dramatically while the share price has remained relatively subdued for years. Revenue has grown manyfold, profitability has improved, and the company has become a much larger healthcare platform, yet the stock has not reflected that progress to the extent many shareholders expected.
That doesn’t necessarily mean the market is wrong—it may be pricing in risks such as acquisition integration, leverage, reimbursement changes, or a preference for faster-growing software businesses. But it does explain why some investors view WELL as undervalued.
If WELL continues to execute and the market begins to assign it valuation multiples closer to other profitable healthcare technology companies, it’s understandable why some investors see significant upside potential. The key question is not whether WELL has grown—it clearly has—but whether the market will eventually place a higher value on those earnings and cash flows.
